Definium net loss more than doubled to $159 million in Q2 FY26
DFTX•Cash position and clinical milestones
Cash, cash equivalents and investments totaled about $1.1 billion at June 30, up from $411.6 million at Dec. 31, 2025; cash runway is seen into 2030.
The company completed a public offering raising $805 million in gross proceeds; net proceeds were about $757.9 million.
Definium also reported positive Phase 3 Emerge topline results in MDD. Phase 3 Voyage GAD data are due the week of Aug. 10, with Panorama GAD data expected in September.
Q2 loss widened on warrant revaluation and higher expenses
Definium Therapeutics posted a Q2 net loss of $159 million versus $42.7 million a year earlier, driven by an $86.2 million non-cash warrant liability revaluation.
R&D expense rose to $48.7 million from , while G&A climbed to from .
